Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

M1750000

Methylprednisolone

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

6α-Methylprednisolone, 11β,17α,21-Trihydroxy-6α-methyl-1,4-pregnadiene-3,20-dione, 6α-Methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione, Medrol, Medrone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H30O5
CAS Number:
83-43-2
Molecular Weight:
374.47
Beilstein:
2340300
MDL number:
MFCD00010591
UNSPSC Code:
41116107
PubChem Substance ID:
329817706
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

methylprednisolone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

wet ice

SMILES string

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

InChI key

VHRSUDSXCMQTMA-PJHHCJLFSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Methylprednisolone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1435003

Methylprednisolone, United States Pharmacopeia (USP) Reference Standard

1437009

Methylprednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard

M1755200

Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard

M1755220

Methylprednisolone hydrogen succinate for performance test, European Pharmacopoeia (EP) Reference Standard

M1755000

Methylprednisolone acetate, European Pharmacopoeia (EP) Reference Standard

1436006

Methylprednisolone acetate, United States Pharmacopeia (USP) Reference Standard

PHR1718

Methylprednisolone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001759

Methylprednisolone hydrogen succinate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001736

Methylprednisolone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001760

Methylprednisolone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001799

Methylprednisolone for system suitability A, European Pharmacopoeia (EP) Reference Standard

1435036

Methylprednisolone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1435014

Methylprednisolone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP248

Methylprednisolone, British Pharmacopoeia (BP) Reference Standard

BP249

Methylprednisolone acetate, British Pharmacopoeia (BP) Reference Standard

BP572

Deltamedrane, British Pharmacopoeia (BP) Reference Standard

1437042

Methyl Prednisolone Hemisuccinate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1437020

Methylprednisolone Hemisuccinate Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR3043

Methylprednisolone Related Compound C, pharmaceutical secondary standard, certified reference material

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360FD,H373

Hazard Classifications

Repr. 1B - STOT RE 2

Target Organs

Adrenal gland,Immune system

WGK

WGK 2

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

MMWR. Morbidity and mortality weekly report, 62(19), 377-381 (2013-05-17)
As of May 6, 2013, Michigan had reported 167 (52%) of the 320 paraspinal or spinal infections without meningitis associated with the 2012-2013 fungal meningitis outbreak nationally. Although the index patient had a laboratory-confirmed Aspergillus fumigatus infection, the fungus most
Ornulf Paulsen et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(29), 3221-3228 (2014-07-09)
Corticosteroids are frequently used in cancer pain management despite limited evidence. This study compares the analgesic efficacy of corticosteroid therapy with placebo. Adult patients with cancer receiving opioids with average pain intensity ≥ 4 (numeric rating scale [NRS], 0 to
Emilio Portaccio et al.
Journal of neurology, neurosurgery, and psychiatry, 85(8), 845-850 (2014-01-10)
To assess relapses, disability progression and the role of disease modifying drugs (DMDs) in the year after delivery in women with multiple sclerosis (MS). We prospectively followed-up pregnancies occurring between 2002 and 2008 in women with MS, recruited from 21
Robert J Fox et al.
Neurology, 82(17), 1491-1498 (2014-04-01)
RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients
Amy L Samuels et al.
British journal of haematology, 165(1), 57-66 (2014-01-25)
Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children. Up to 25% of patients with T-cell ALL (T-ALL) develop resistance to chemotherapeutic agents, particularly to glucocorticoids (GCs), a class of drug to
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service